Skip to main content
SpringerLink
Log in

MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line

  • Original Article
  • Published:
Irish Journal of Medical Science (1971 -) Aims and scope Submit manuscript

Abstract

Background

Recent studies have shown that microRNA-21 (miR-21) is overexpressed in solid tumors and implicated in the modulation of drug-induced resistance.

Methods

In this study, we investigated the anti-tumor effects of miR-21 on the sensitivity of osteosarcoma cells to CDDP.

Results

Changes in the sensitivity of osteosarcoma cells to CDDP were examined after transfection with miR-21 mimics or anti-miR-21 or bcl-2 siRNA in combination with CDDP. Osteosarcoma cells transfected with miR-21 mimics were significantly resistant to CDDP, while suppression of miR-21 in osteosarcoma cells led to enhanced CDDP cytotoxicity. Moreover, the miR-21-induced changes in chemoresponse were ameliorated by down-regulation of bcl-2 by its siRNA.

Conclusion

The miR-21 in osteosarcoma cells is a significant modulator of the anti-tumor effect of CDDP by regulating the expression of bcl-2, and the study reveals a novel mechanism of osteosarcoma drug resistance.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Pillai RS (2005) MicroRNA function: multiple mechanisms for a tiny RNA? RNA 11:1753–1761

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  2. Zamore PD, Haley B (2005) Ribo-gnome: the big world of small RNAs. Science 309:1519–1524

    Article  PubMed  CAS  Google Scholar 

  3. Chen CZ, Li L, Lodish HF et al (2004) MicroRNAs modulate hematopoietic lineage differentiation. Science 303:83–86

    Article  PubMed  CAS  Google Scholar 

  4. Croce CM, Calin GA (2005) miRNAs, cancer, and stem cell division. Cell 122:6–7

    Article  PubMed  CAS  Google Scholar 

  5. Chan JA, Krichevsky AM, Kosik KS (2005) MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res 65:6029–6033

    Article  PubMed  CAS  Google Scholar 

  6. Iorio MV, Ferracin M, Liu CG et al (2005) MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65:7065–7070

    Article  PubMed  CAS  Google Scholar 

  7. Diederichs S, Haber DA (2006) Sequence variations of microRNAs in human cancer: alterations in predicted secondary structure do not affect processing. Cancer Res 66:6097–6104

    Article  PubMed  CAS  Google Scholar 

  8. Roldo C, Missiaglia E, Hagan JP et al (2006) MicroRNA expression abnormalities in pancreatic endocrine and acinar tumors are associated with distinctive pathologic features and clinical behavior. J Clin Oncol 24:4677–4684

    Article  PubMed  CAS  Google Scholar 

  9. Volinia S, Calin GA, Liu CG et al (2006) A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103:2257–2261

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  10. Meng F, Henson R, Wehbe-Janek H et al (2007) MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133:647–658

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  11. Giovannetti E, Funel N, Peters GJ et al (2010) MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity. Cancer Res 70:4528–4538

    Article  PubMed  CAS  Google Scholar 

  12. Bourguignon LY, Spevak CC, Wong G et al (2009) Hyaluronan–CD44 interaction with protein kinase C (epsilon) promotes oncogenic signaling by the stem cell marker Nanog and the production of microRNA-21, leading to down-regulation of the tumor suppressor protein PDCD4, anti-apoptosis, and chemotherapy resistance in breast tumor cells. J Biol Chem 284:26533–26546

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  13. Shi L, Chen J, Yang J et al (2010) MiR-21 protected human glioblastoma U87MG cells from chemotherapeutic drug temozolomide induced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity. Brain Res 1352:255–264

    Article  PubMed  CAS  Google Scholar 

  14. Li Y, Li W, Yang Y et al (2009) MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. Brain Res 1286:13–18

    Article  PubMed  CAS  Google Scholar 

  15. Bacci G, Ruggieri P, Picci P et al (1996) Intra-arterial versus intravenous cisplatinum (in addition to systemic Adriamycin and high dose methotrexate) in the neoadjuvant treatment of osteosarcoma of the extremities. Results of a randomized study. J Chemother 8:70–81

    Article  PubMed  CAS  Google Scholar 

  16. Jaffe N, Knapp J, Chuang VP et al (1983) Osteosarcoma: intra-arterial treatment of the primary tumor with cis-diammine-dichloroplatinum II (CDP). Angiographic, pathologic, and pharmacologic studies. Cancer 51:402–407

    Article  PubMed  CAS  Google Scholar 

  17. Jaffe N (1993) Pediatric osteosarcoma: treatment of the primary tumor with intraarterial cis-diamminedichloroplatinum-II (CDP)—advantages, disadvantages, and controversial issues. Cancer Treat Res 62:75–84

    Article  PubMed  CAS  Google Scholar 

  18. Giaccone G (2000) Clinical perspectives on platinum resistance. Drugs 59:9–17

    Article  PubMed  CAS  Google Scholar 

  19. Huang Y, Anderle P, Bussey KJ et al (2004) Membrane transporters and channels: role of the transportome in cancer chemosensitivity and chemoresistance. Cancer Res 64:4294–4301

    Article  PubMed  CAS  Google Scholar 

  20. McLornan DP, McMullin MF, Johnston P et al (2007) Molecular mechanisms of drug resistance in acute myeloid leukaemia. Expert Opin Drug Metab Toxicol 3:363–377

    Article  PubMed  CAS  Google Scholar 

  21. Bazarbashi S, Abdelsalam M, Amin T et al (2008) Phase II trial of neoadjuvant cisplatin, 5-fluorouracil and interferon-alpha in operable squamous cell carcinoma of the esophagus. Chemotherapy 54:315–322

    Article  PubMed  CAS  Google Scholar 

  22. Blower PE, Chung JH, Verducci JS et al (2008) MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther 7:1–9

    Article  PubMed  CAS  Google Scholar 

  23. Fujita Y, Kojima K, Hamada N et al (2008) Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells. Biochem Biophys Res Commun 377:114–119

    Article  PubMed  CAS  Google Scholar 

  24. Bai S, Nasser MW, Wang B et al (2009) MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem 284:32015–32027

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  25. Fornari F, Gramantieri L, Giovannini C et al (2009) MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 69:5761–5767

    Article  PubMed  CAS  Google Scholar 

  26. Tomimaru Y, Eguchi H, Nagano H et al (2010) MicroRNA-21 induces resistance to the anti-tumour effect of interferon-a/5-fluorouracil in hepatocellular carcinoma cells. Br J Cancer 103:1617–1626

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  27. Bai H, Xu R, Cao Z et al (2011) Involvement of miR-21 in resistance to daunorubicin by regulating PTEN expression in the leukaemia K562 cell line. FEBS Lett 585:402–408

    Article  PubMed  CAS  Google Scholar 

  28. Yang J, Zhang W (2013) New molecular insights into osteosarcoma targeted therapy. Curr Opin Oncol 25:398–406

    Article  PubMed  CAS  Google Scholar 

  29. Ji T, Lin C, Krill LS et al (2013) Flavokawain B, a kava chalcone, inhibits growth of human osteosarcoma cells through G2/M cell cycle arrest and apoptosis. Mol Cancer 12:55

    Article  PubMed  CAS  PubMed Central  Google Scholar 

  30. Si ML, Zhu S, Wu H et al (2007) miR-21-mediated tumor growth. Oncogene 26:2799–2803

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgments

This research was supported by Wuhan City (Hubei, China) Health Bureau project (No: WX13C34).

Author information

Authors and Affiliations

  1. Department of Orthopedics, Fifth Hospital of Wuhan, Hubei, 430050, People’s Republic of China

    W. Ziyan & L. Yang

Authors
  1. W. Ziyan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. L. Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to W. Ziyan.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ziyan, W., Yang, L. MicroRNA-21 regulates the sensitivity to cisplatin in a human osteosarcoma cell line. Ir J Med Sci 185, 85–91 (2016). https://doi.org/10.1007/s11845-014-1225-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11845-014-1225-x

Keywords

Search

Navigation